Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...

Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...

Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Cassava Sciences shares fell in premarket trading Friday after regulators said the company, along with two former executives, will pay more than $40 million to settle charges related to misleading ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...

Relatedly, the SEC also charged Hoau-Yan Wang, a Cassava consultant and an associate professor at the City University of New York's Medical School, for manipulating the reported clinical trial results ...